Members Of Purdue Public Record Disclosure Board Named

Entities representing groups of opioid claimants in the Chapter 11 case of Purdue Pharma have named their representatives on an oversight board created to implement a public repository of documents related to the national opioid epidemic and Purdue’s role in the crisis.

In a notice published Friday on the case docket for Purdue’s bankruptcy in New York, the 14 volunteer members of the disclosure oversight board were listed. This body is tasked with arranging for a permanent public repository for 100 million pages of documents associated with Purdue’s OxyContin marketing and sales tactics.

Under the terms of Purdue’s confirmed Chapter 11 plan, a public document repository is to be created to house the millions of documents possessed by Purdue or produced by the company in the years of criminal and civil litigation tied to its OxyContin products. Many of those records were not previously made publicly available and will include internal emails among the company’s leadership and formerly privileged documents.

The public document repository to be implemented by the board was a key piece of a global settlement of the Purdue Chapter 11 case, which began in September 2019 and resulted in at least $7.4 billion of payments from the company and its owners to satisfy claims brought by local and state governments, Native American tribes, and personal injury and wrongful death claimants.

The repository is aimed at showing the events and decisions that led to the national crisis around opioids through the marketing of products like OxyContin by Purdue, with the goal of preventing further crises of that nature.

A Chapter 11 plan confirmed by a New York bankruptcy judge was overturned by the U.S. Supreme Court in June 2024 when the high court decided that the nonconsensual third-party releases of nondebtors included in that plan were not permitted under the Bankruptcy Code. The original plan included billions of dollars in settlement payments from the Sacklers in exchange for a release of liability for claims brought by thousands of nondebtor entities.

The newest confirmed plan, approved by U.S. Bankruptcy Judge Sean H. Lane in November 2025, calls for those claimants to opt in to granting releases to the Sacklers to share in the distribution from the owners of the company. If the claimants chose not to grant the releases, their rights to sue the Sacklers would survive the bankruptcy.

Other nonmonetary relief included in the plan are the Sacklers’ exit from the company and the opioid business, as well as the conversion of Purdue into a public benefit corporation called Knoa Pharma, which will continue to sell pharmaceuticals with excess profits being channeled to opioid abatement efforts.

The oversight board members are appointed by the ad hoc committee of government and other litigation claimants, the unsecured creditors committee, the state attorneys general negotiating group, and the multi-state governmental entities group, each of which selects four members, and the Native American tribe group, which can select one member.

The notice listed 14 members, with the multi-state governmental entities group naming one member.

The ad hoc committee named the following members to the board: Jayne Conroy of Simmons Hanly Conroy, co-lead counsel for plaintiffs in the national prescription opiate multidistrict litigation; the Florida Attorney General’s Office; the Ohio Attorney General’s Office; and the City of Philadelphia.

The unsecured creditors committee named the following as members: Justin Alberto of Cole Schotz PC, which served as conflicts and efficiency counsel for the committee in the Purdue Chapter 11; Cyrus Mehri of Mehri & Skalet, lead counsel for a class of public schools that brought claims against opioid defendants; Kevin Thompson of Thompson Barney, counsel for a member of the creditors committee; and Kara Trainor, a member of the creditors committee.

To read the full article, click here.